Several mechanisms involve miRNA in the development of melanoma resistance to BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi), which block the MAPK pathway; this limits their prolonged use [79,80,81]. The gene discussed is BRAF; the disease is melanoma.